肝脏中外排转运蛋白的研究展望。
A perspective on efflux transport proteins in the liver.
机构信息
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.
出版信息
Clin Pharmacol Ther. 2012 Nov;92(5):599-612. doi: 10.1038/clpt.2012.79. Epub 2012 Sep 5.
Abstract
Detailed knowledge regarding the influence of hepatic transport proteins on drug disposition has advanced at a rapid pace over the past decade. Efflux transport proteins located in the basolateral and apical (canalicular) membranes of hepatocytes play an important role in the hepatic elimination of many endogenous and exogenous compounds, including drugs and metabolites. This review focuses on the role of these efflux transporters in hepatic drug excretion. The impact of these proteins as underlying factors for disease is highlighted, and the importance of hepatic efflux proteins in the efficacy and toxicity of drugs is discussed. In addition, a brief overview of methodology to evaluate the function of hepatic efflux transport proteins is provided. Current challenges in predicting the impact of altered efflux protein function on systemic, intestinal, and hepatocyte exposure to drugs and metabolites are highlighted.
摘要
在过去的十年中，人们对肝转运蛋白对药物处置的影响的了解取得了飞速的发展。位于肝细胞基底外侧和顶膜（胆小管）的外排转运蛋白在许多内源性和外源性化合物（包括药物和代谢物）的肝消除中发挥着重要作用。这篇综述重点介绍了这些外排转运蛋白在肝药物排泄中的作用。强调了这些蛋白作为疾病基础因素的作用，并讨论了肝外排蛋白在药物疗效和毒性中的重要性。此外，还简要概述了评估肝外排转运蛋白功能的方法学。强调了预测改变外排蛋白功能对药物和代谢物全身、肠道和肝细胞暴露影响方面所面临的挑战。
相似文献
1
A perspective on efflux transport proteins in the liver.肝脏中外排转运蛋白的研究展望。
Clin Pharmacol Ther. 2012 Nov;92(5):599-612. doi: 10.1038/clpt.2012.79. Epub 2012 Sep 5.
2
Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.肝脏转运体在药物及其代谢产物临床处置中的重要性。
J Clin Pharmacol. 2016 Jul;56 Suppl 7:S23-39. doi: 10.1002/jcph.671.
3
Sandwich-Cultured Hepatocytes for Mechanistic Understanding of Hepatic Disposition of Parent Drugs and Metabolites by Transporter-Enzyme Interplay.夹心培养肝细胞用于通过转运体-酶相互作用对原药及其代谢物的肝处置机制的理解。
Drug Metab Dispos. 2018 May;46(5):680-691. doi: 10.1124/dmd.117.079236. Epub 2018 Jan 19.
4
Role of hepatic efflux transporters in regulating systemic and hepatocyte exposure to xenobiotics.肝脏外排转运体在调节异生物质的全身和肝细胞暴露中的作用。
Annu Rev Pharmacol Toxicol. 2014;54:509-35. doi: 10.1146/annurev-pharmtox-011613-140021. Epub 2013 Oct 23.
5
Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.细胞内药物浓度和转运体：测量、建模及其对肝脏的影响。
Clin Pharmacol Ther. 2013 Jul;94(1):126-41. doi: 10.1038/clpt.2013.78. Epub 2013 Apr 10.
6
Interaction of Drug or Food with Drug Transporters in Intestine and Liver.药物或食物与肠道和肝脏中药物转运体的相互作用。
Curr Drug Metab. 2015;16(9):753-64. doi: 10.2174/138920021609151201113537.
7
Liver transporters in hepatic drug disposition: an update.肝脏药物处置中的肝转运体：最新进展
Curr Drug Metab. 2009 Jun;10(5):482-98. doi: 10.2174/138920009788898037.
8
Roles of Hepatic Drug Transporters in Drug Disposition and Liver Toxicity.肝药物转运体在药物处置和肝毒性中的作用。
Adv Exp Med Biol. 2019;1141:293-340. doi: 10.1007/978-981-13-7647-4_6.
9
Understanding the Interplay Between Uptake and Efflux Transporters Within In Vitro Systems in Defining Hepatocellular Drug Concentrations.了解摄取和外排转运体在体外系统中相互作用，以定义肝细胞内药物浓度。
J Pharm Sci. 2017 Sep;106(9):2815-2825. doi: 10.1016/j.xphs.2017.04.056. Epub 2017 May 3.
10
Membrane transport as a determinant of the hepatic elimination of drugs and metabolites.膜转运作为肝脏对药物和代谢物消除的一个决定因素。
Clin Exp Pharmacol Physiol. 1996 Oct-Nov;23(10-11):970-4. doi: 10.1111/j.1440-1681.1996.tb01151.x.
引用本文的文献
1
Multidrug Resistance-Associated Proteins 3 and 5 Play a Role in the Hepatic Transport of Mercuric Conjugates of Glutathione.多药耐药相关蛋白3和5在谷胱甘肽汞共轭物的肝脏转运中发挥作用。
Int J Mol Sci. 2025 Jan 30;26(3):1194. doi: 10.3390/ijms26031194.
2
Does Bisphenol A (BPA) Exposure Cause Human Diseases?双酚A（BPA）暴露会引发人类疾病吗？
Biomedicines. 2024 Nov 25;12(12):2678. doi: 10.3390/biomedicines12122678.
3
Overcoming Challenges in Small-Molecule Drug Bioavailability: A Review of Key Factors and Approaches.克服小分子药物生物利用度的挑战：关键因素与方法综述
Int J Mol Sci. 2024 Dec 6;25(23):13121. doi: 10.3390/ijms252313121.
4
Impact of pregnancy related hormones on drug metabolizing enzyme and transport protein concentrations in human hepatocytes.妊娠相关激素对人肝细胞中药物代谢酶和转运蛋白浓度的影响。
Front Pharmacol. 2022 Sep 21;13:1004010. doi: 10.3389/fphar.2022.1004010. eCollection 2022.
5
Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells.在人肝癌 HepaRG 细胞中，胆汁淤积药物抑制胆小管和窦状隙胆盐水流出。
Biopharm Drug Dispos. 2022 Dec;43(6):265-271. doi: 10.1002/bdd.2333. Epub 2022 Oct 27.
6
Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis.基于模型的群体药代动力学分析：药物遗传学对儿科患者口服长春瑞滨暴露变异性的影响。
Cancer Chemother Pharmacol. 2022 Jul;90(1):29-44. doi: 10.1007/s00280-022-04446-y. Epub 2022 Jun 25.
7
Mouse precision-cut liver slices as an ex vivo model to study drug-induced cholestasis.小鼠离体肝切片作为研究药物性胆汁淤积的体外模型。
Arch Toxicol. 2022 Sep;96(9):2523-2543. doi: 10.1007/s00204-022-03321-2. Epub 2022 Jun 16.
8
Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.新型 GPR40（FFAR1）激动剂 CPL207280 在大鼠和猴体内的肝毒性评价。
PLoS One. 2021 Sep 23;16(9):e0257477. doi: 10.1371/journal.pone.0257477. eCollection 2021.
9
Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.基于生理学的转运体介导的大鼠成像生物标志物钆塞酸在肝内处置的药代动力学模型。
Mol Pharm. 2021 Aug 2;18(8):2997-3009. doi: 10.1021/acs.molpharmaceut.1c00206. Epub 2021 Jul 20.
10
Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.健康志愿者中别嘌醇的药代动力学和药效学：BCRP Q141K 多态性和患者特征的影响。
Clin Transl Sci. 2021 Jul;14(4):1431-1443. doi: 10.1111/cts.12992. Epub 2021 May 1.
本文引用的文献
1
Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway.在人类梗阻性胆汁淤积中，肝多药耐药相关蛋白 3/ATP 结合盒亚家族 C3 的表达升高是通过肿瘤坏死因子α和 c-Jun NH2-末端激酶/应激激活蛋白激酶信号通路介导的。
Hepatology. 2012 May;55(5):1485-94. doi: 10.1002/hep.24801.
2
MALDI imaging mass spectrometry: bridging biology and chemistry in drug development.基质辅助激光解吸电离成像质谱：在药物研发中架起生物学与化学的桥梁
Bioanalysis. 2011 Nov;3(21):2427-41. doi: 10.4155/bio.11.232.
3
Strategies to produce hepatocytes and hepatocyte-like cells from pluripotent stem cells.从多能干细胞生产肝细胞和肝样细胞的策略。
Hepatol Res. 2012 Feb;42(2):111-9. doi: 10.1111/j.1872-034X.2011.00896.x. Epub 2011 Oct 11.
4
Canalicular ABC transporters and liver disease.胆小管 ABC 转运体与肝脏疾病。
J Pathol. 2012 Jan;226(2):300-15. doi: 10.1002/path.3019.
5
Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells.使用三重转染的 MDCK-OATP1B1-UGT1A1-MRP2 细胞鉴定多药耐药蛋白 2（MRP2）的药物和药物代谢物作为其底物。
Br J Pharmacol. 2012 Mar;165(6):1836-1847. doi: 10.1111/j.1476-5381.2011.01672.x.
6
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.伊立替康活性和毒性的药代动力学和遗传预测标志物。
Curr Drug Metab. 2011 Dec;12(10):932-43. doi: 10.2174/138920011798062283.
7
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.质子泵抑制剂通过诱导菌群失调加剧 NSAID 引起的小肠损伤。
Gastroenterology. 2011 Oct;141(4):1314-22, 1322.e1-5. doi: 10.1053/j.gastro.2011.06.075. Epub 2011 Jul 13.
8
Systematic screening of human ABCC3 polymorphisms and their effects on MRP3 expression and function.ABCC3 多态性的系统筛选及其对 MRP3 表达和功能的影响。
Drug Metab Pharmacokinet. 2011;26(4):374-86. doi: 10.2133/dmpk.dmpk-10-rg-103. Epub 2011 Apr 22.
9
NSAID acyl glucuronides and enteropathy.非甾体抗炎药酰基葡萄糖醛酸化物与肠病。
Curr Drug Metab. 2011 Mar;12(3):245-52. doi: 10.2174/138920011795101877.
10
Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.有机阴离子转运多肽 1B1：一种遗传多态性转运体，对肝脏药物摄取具有重要意义。
Pharmacol Rev. 2011 Mar;63(1):157-81. doi: 10.1124/pr.110.002857. Epub 2011 Jan 18.
Zotero 插件